Physiological Significance of Reactive Cysteine Residues of Keap1 in Determining Nrf2 Activity

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2008 Feb 13

PMID 18268004

Citations 237

Authors

Tae Yamamoto

Takafumi Suzuki

Akira Kobayashi

Junko Wakabayashi

Jon Maher

Hozumi Motohashi

Masayuki Yamamoto

Affiliations

Soon will be listed here.

Abstract

Keap1 and Cul3 constitute a unique ubiquitin E3 ligase that degrades Nrf2, a key activator of cytoprotective genes. Upon exposure to oxidants/electrophiles, the enzymatic activity of this ligase complex is inhibited and the complex fails to degrade Nrf2, resulting in the transcriptional activation of Nrf2 target genes. Keap1 possesses several reactive cysteine residues that covalently bond with electrophiles in vitro. To clarify the functional significance of each Keap1 cysteine residue under physiological conditions, we established a transgenic complementation rescue model. The transgenic expression of mutant Keap1(C273A) and/or Keap1(C288A) protein in Keap1 null mice failed to reverse constitutive Nrf2 activation, indicating that cysteine residues at positions 273 and 288 are essential for Keap1 to repress Nrf2 activity in vivo. In contrast, Keap1(C151S) retained repressor activity and mice expressing this molecule were viable. Mouse embryonic fibroblasts from Keap1(C151S) transgenic mice displayed decreased expression of Nrf2 target genes both before and after an electrophilic challenge, suggesting that Cys151 is important in facilitating Nrf2 activation. These results demonstrate critical roles of the cysteine residues in vivo in maintaining Keap1 function, such that Nrf2 is repressed under quiescent conditions and active in response to oxidants/electrophiles.

Citing Articles

Thirty years of NRF2: advances and therapeutic challenges.

Zhang D Nat Rev Drug Discov. 2025; .

PMID: 40038406 DOI: 10.1038/s41573-025-01145-0.

Ameliorates Doxorubicin-Induced Nephrotoxicity and Potentiates Its Therapeutic Efficacy Targeting SIRT1/Nrf2, Oxidative Stress, Inflammation, and Apoptosis.

Mohmmed Hegab A, Hassanin S, Mekky R, Abuzahrah S, Hamza A, Talaat I Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006061 PMC: 11859695. DOI: 10.3390/ph18020248.

Model organisms for investigating the functional involvement of NRF2 in non-communicable diseases.

Rojo A, Buttari B, Cadenas S, Carlos A, Cuadrado A, Falcao A Redox Biol. 2024; 79():103464.

PMID: 39709790 PMC: 11733061. DOI: 10.1016/j.redox.2024.103464.

Emerging perspectives of copper-mediated transcriptional regulation in mammalian cell development.

Fitisemanu F, Padilla-Benavides T Metallomics. 2024; 16(10).

PMID: 39375833 PMC: 11503025. DOI: 10.1093/mtomcs/mfae046.

Epigallocatechin-3-Gallate Inhibits Oxidative Stress Through the Keap1/Nrf2 Signaling Pathway to Improve Alzheimer Disease.

Tang S, Zhang Y, Botchway B, Wang X, Huang M, Liu X Mol Neurobiol. 2024; 62(3):3493-3507.

PMID: 39299981 DOI: 10.1007/s12035-024-04498-6.

References

Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

Katsuoka F, Motohashi H, Ishii T, Aburatani H, Engel J, Yamamoto M . Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. Mol Cell Biol. 2005; 25(18):8044-51. PMC: 1234339. DOI: 10.1128/MCB.25.18.8044-8051.2005. View

Hong F, Freeman M, Liebler D . Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol. 2005; 18(12):1917-26. DOI: 10.1021/tx0502138. View

Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S . Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet. 2003; 35(3):238-45. DOI: 10.1038/ng1248. View

Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y . An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236(2):313-22. DOI: 10.1006/bbrc.1997.6943. View

Tong K, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M . Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol Cell Biol. 2006; 26(8):2887-900. PMC: 1446969. DOI: 10.1128/MCB.26.8.2887-2900.2006. View

Padmanabhan B, Tong K, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M . Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell. 2006; 21(5):689-700. DOI: 10.1016/j.molcel.2006.01.013. View

Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel J . Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999; 13(1):76-86. PMC: 316370. DOI: 10.1101/gad.13.1.76. View

McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes J . Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J Biol Chem. 2006; 281(34):24756-68. DOI: 10.1074/jbc.M601119200. View

10.

Watai Y, Kobayashi A, Nagase H, Mizukami M, McEvoy J, Singer J . Subcellular localization and cytoplasmic complex status of endogenous Keap1. Genes Cells. 2007; 12(10):1163-78. DOI: 10.1111/j.1365-2443.2007.01118.x. View

11.

Katoh Y, Iida K, Kang M, Kobayashi A, Mizukami M, Tong K . Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch Biochem Biophys. 2004; 433(2):342-50. DOI: 10.1016/j.abb.2004.10.012. View

12.

Tiemann F, Deppert W . Immortalization of BALB/c mouse embryo fibroblasts alters SV40 large T-antigen interactions with the tumor suppressor p53 and results in a reduced SV40 transformation-efficiency. Oncogene. 1994; 9(7):1907-15. View

13.

Kang M, Kobayashi A, Wakabayashi N, Kim S, Yamamoto M . Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc Natl Acad Sci U S A. 2004; 101(7):2046-51. PMC: 357049. DOI: 10.1073/pnas.0308347100. View

14.

Kobayashi M, Itoh K, Suzuki T, Osanai H, Nishikawa K, Katoh Y . Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system. Genes Cells. 2002; 7(8):807-20. DOI: 10.1046/j.1365-2443.2002.00561.x. View

15.

Kobayashi A, Kang M, Okawa H, Ohtsuji M, Zenke Y, Chiba T . Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24(16):7130-9. PMC: 479737. DOI: 10.1128/MCB.24.16.7130-7139.2004. View

16.

Zhang D, Lo S, Cross J, Templeton D, Hannink M . Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol. 2004; 24(24):10941-53. PMC: 533977. DOI: 10.1128/MCB.24.24.10941-10953.2004. View

17.

Levonen A, Landar A, Ramachandran A, Ceaser E, Dickinson D, Zanoni G . Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J. 2003; 378(Pt 2):373-82. PMC: 1223973. DOI: 10.1042/BJ20031049. View

18.

Motohashi H, Katsuoka F, Engel J, Yamamoto M . Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. Proc Natl Acad Sci U S A. 2004; 101(17):6379-84. PMC: 404053. DOI: 10.1073/pnas.0305902101. View

19.

Dinkova-Kostova A, Holtzclaw W, Cole R, Itoh K, Wakabayashi N, Katoh Y . Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002; 99(18):11908-13. PMC: 129367. DOI: 10.1073/pnas.172398899. View

20.

Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler T, Yamamoto M . Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun. 2005; 339(1):79-88. DOI: 10.1016/j.bbrc.2005.10.185. View